QSAR study on aminophenylbenzamides and acrylamides as histone deacetylase inhibitors: An insight into the structural basis of antiproliferative activity

Histone deacetylases have emerged as important drug target with a multitude of therapeutic potentials for their inhibitors. With the purpose of designing new chemical entities with enhanced inhibitory potencies against histone deacetylases, a two-dimensional (2D) quantitative structure-activity relationship (QSAR) study was carried out on aminophenylbenzamides and acrylamide derivatives as inhibitors of these deacetylases. The developed model was validated by standard QSAR parameters and through a detailed structural analysis of how it reproduces and explains the differences in the experimentally known activity data. The model showed a good correlative and predictive ability, with a cross-validated correlation coefficient of 0.594. The conventional and predictive correlation coefficients were found to be 0.725 and 0.577 for the antiproliferative activity of aminophenylbenzamides and acrylamide series, respectively. The study indicated that their antiproliferative activity is largely explained by the steric factors of the substituents, highlighting the role of the size and shape of the inhibitor in forming effective binding interactions with histone deacetylase. The models could be usefully employed to design inhibitors with greatly enhanced potency and selectivity.

[1]  G. Suchowsky,et al.  BIOLOGICAL ACTIVITY AND CHEMICAL STRUCTURE. , 1963, Nihon Naibunpi Gakkai zasshi.

[2]  A. Verloop,et al.  Development and Application of New Steric Substituent Parameters in Drug Design , 1976 .

[3]  J. Tipker,et al.  Use of linear free energy related and other parameters in the study of fungicidal selectivity , 1976 .

[4]  K. Anderson,et al.  Changing rates of histone mRNA synthesis and turnover in Drosophila embryos , 1980, Cell.

[5]  H. Kubinyi.  QSAR and 3D QSAR in drug design Part 1: methodology , 1997 .

[6]  I. Gilbert,et al.  A QSAR study investigating the effect of L-alanine ester variation on the anti-HIV activity of some phosphoramidate derivatives of d4T. , 2000, Bioorganic & medicinal chemistry letters.

[7]  Design and synthesis of a novel class of histone deacetylase inhibitors. , 2001, Bioorganic & medicinal chemistry letters.

[8]  P. Pandolfi.  Transcription therapy for cancer , 2001, Oncogene.

[9]  T. Yamori,et al.  Novel histone deacetylase inhibitors: N-hydroxycarboxamides possessing a terminal bicyclic aryl group. , 2002, Bioorganic & medicinal chemistry letters.

[10]  K. Glaser,et al.  Histone deacetylase inhibitors: the Abbott experience. , 2003, Current medicinal chemistry.

[11]  P. Finn,et al.  The cell cycle, chromatin and cancer: mechanism-based therapeutics come of age. , 2003, Drug discovery today.

[12]  Alexander Golbraikh,et al.  QSAR Modeling of alpha-Campholenic Derivatives with Sandalwood Odor , 2003, J. Chem. Inf. Comput. Sci..

[13]  P. Wolschann,et al.  Bayesian Neural Networks for Aroma Classification. , 2003 .

[14]  M. Esteller,et al.  Histone deacetylase inhibitors: Understanding a new wave of anticancer agents , 2004, International journal of cancer.

[15]  B. Djulbegovic.  High-quality evidence in oncology from 8th December to 16th December 2003: a summary , 2004 .

[16]  Minoru Yoshida,et al.  Novel histone deacetylase inhibitors: cyclic tetrapeptide with trifluoromethyl and pentafluoroethyl ketones. , 2004, Bioorganic & Medicinal Chemistry Letters.

[17]  S. Izraeli,et al.  Histone deacetylase inhibitors--a new tool to treat cancer. , 2004, Cancer treatment reviews.

[18]  Minoru Yoshida,et al.  Chlamydocin-hydroxamic acid analogues as histone deacetylase inhibitors. , 2004, Bioorganic & medicinal chemistry.

[19]  H. Weinmann,et al.  Recent Advances in Medicinal Chemistry of Histone Deacetylase Inhibitors , 2004 .

[20]  N. L. La Thangue,et al.  Histone deacetylase inhibitors open new doors in cancer therapy. , 2004, Biochemical pharmacology.

[21]  M. Jung,et al.  Chemistry and biology of mercaptoacetamides as novel histone deacetylase inhibitors. , 2005, Bioorganic & medicinal chemistry letters.

[22]  Y. Hashimoto,et al.  Design and synthesis of phthalimide-type histone deacetylase inhibitors. , 2005, Bioorganic & medicinal chemistry letters.

[23]  C. Monneret.  Histone deacetylase inhibitors. , 2005, European journal of medicinal chemistry.

[24]  N. L. La Thangue,et al.  Chromatin control and cancer-drug discovery: realizing the promise. , 2006, Drug discovery today.

[25]  N. L. La Thangue,et al.  Histone deacetylase inhibitors: gathering pace. , 2006, Current opinion in pharmacology.

[26]  Neha S. Gandhi,et al.  3D QSAR studies of N-4-arylacryloylpiperazin-1-yl-phenyl-oxazolidinones: a novel class of antibacterial agents. , 2006, Bioorganic & Medicinal Chemistry Letters.

[27]  A. Kalita,et al.  Substituted N-(2-aminophenyl)-benzamides, (E)-N-(2-aminophenyl)-acrylamides and their analogues: novel classes of histone deacetylase inhibitors. , 2006, Bioorganic & medicinal chemistry letters.

[28]  S. Singh,et al.  3D‐QSAR CoMFA Study on Aminothiazole Derivatives as Cyclin‐Dependent Kinase 2 Inhibitors , 2007 .

[29]  N. Dessalew,et al.  3D-QSAR and molecular docking study on bisarylmaleimide series as glycogen synthase kinase 3, cyclin dependent kinase 2 and cyclin dependent kinase 4 inhibitors: an insight into the criteria for selectivity. , 2007, European journal of medicinal chemistry.

[30]  Dhilon S. Patel,et al.  3D-QSAR and molecular docking studies on pyrazolopyrimidine derivatives as glycogen synthase kinase-3beta inhibitors. , 2007, Journal of molecular graphics & modelling.

[31]  H. Chun,et al.  Quantitative structure-activity relationship (QSAR) for neuroprotective activity of terpenoids. , 2007, Life sciences.

[32]  James M. Morrell,et al.  Structure-activity relationships of aryloxyalkanoic acid hydroxyamides as potent inhibitors of histone deacetylase. , 2007, Bioorganic & medicinal chemistry letters.